These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 22457321)

  • 21. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degarelix: a review of its use in patients with prostate cancer.
    Carter NJ; Keam SJ
    Drugs; 2014 Apr; 74(6):699-712. PubMed ID: 24756432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
    Beer TM; Ryan C; Bhat G; Garnick M;
    Anticancer Drugs; 2006 Oct; 17(9):1075-9. PubMed ID: 17001181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degarelix and its therapeutic potential in the treatment of prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Clin Interv Aging; 2009; 4():215-23. PubMed ID: 19503784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
    Klotz L
    Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
    Raddin RS; Walko CM; Whang YE
    Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.